MedTrace Logo

Onabotulinumtoxin A Versus Kenalog for Chronic Pelvic Pain

NCT02369068 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2019-07-24

Study results available
· View outcomes & findings →

Summary

The goal of this study is to compare the effectiveness of two different medications used in intravaginal trigger point injections (injections into extremely painful areas of a muscle) to treat chronic pelvic pain. The study compares onabotulinumtoxinA (BOTOX®) (a drug prepared from the bacterial toxin botulin which temporarily paralyzes muscles) to Kenalog (a synthetic corticosteroid used as an anti-inflammatory agent).

Conditions

  • Pelvic Pain

Interventions

DRUG

Onabotulinumtoxin A

Intravaginal pelvic floor injection one series

DRUG

Kenalog

Intravaginal pelvic floor injection one series

Sponsors & Collaborators

  • Jamie Bartley, DO

    lead OTHER

Principal Investigators

  • Jamie Bartley, DO · Beaumont

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-08-31
Primary Completion
2018-03-26
Completion
2018-09-24

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02369068 on ClinicalTrials.gov